Joglekar A, Li G
Nat Methods. 2020; 18(8):873-880.
PMID: 32632239
DOI: 10.1038/s41592-020-0867-z.
Brown L, Gaffney E, Wagg J, Coles M
J R Soc Interface. 2018; 15(140).
PMID: 29540543
PMC: 5908537.
DOI: 10.1098/rsif.2018.0041.
Lowe D, Bivens C, Mobley A, Herrera C, McCormick A, Wichner T
MAbs. 2017; 9(4):603-614.
PMID: 28273004
PMC: 5419083.
DOI: 10.1080/19420862.2017.1302630.
Bentzen A, Marquard A, Lyngaa R, Saini S, Ramskov S, Donia M
Nat Biotechnol. 2016; 34(10):1037-1045.
PMID: 27571370
DOI: 10.1038/nbt.3662.
Kumari S, Walchli S, Fallang L, Yang W, Lund-Johansen F, Schumacher T
Proc Natl Acad Sci U S A. 2013; 111(1):403-8.
PMID: 24344295
PMC: 3890872.
DOI: 10.1073/pnas.1306549111.
HLA ligandome tumor antigen discovery for personalized vaccine approach.
Rammensee H, Singh-Jasuja H
Expert Rev Vaccines. 2013; 12(10):1211-7.
PMID: 24090147
PMC: 3821395.
DOI: 10.1586/14760584.2013.836911.
Mouse urinary peptides provide a molecular basis for genotype discrimination by nasal sensory neurons.
Sturm T, Leinders-Zufall T, Macek B, Walzer M, Jung S, Pommerl B
Nat Commun. 2013; 4:1616.
PMID: 23511480
DOI: 10.1038/ncomms2610.
A stochastic T cell response criterion.
Currie J, Castro M, Lythe G, Palmer E, Molina-Paris C
J R Soc Interface. 2012; 9(76):2856-70.
PMID: 22745227
PMC: 3479899.
DOI: 10.1098/rsif.2012.0205.
Specific T-cell activation in an unspecific T-cell repertoire.
van den Berg H, Molina-Paris C, Sewell A
Sci Prog. 2011; 94(Pt 3):245-64.
PMID: 22026148
PMC: 10365486.
DOI: 10.3184/003685011X13139280383942.
CTL recognition of a novel HLA-A*0201-binding peptide derived from glioblastoma multiforme tumor cells.
Myers C, Hanavan P, Antwi K, Mahadevan D, Nadeem A, Cooke L
Cancer Immunol Immunother. 2011; 60(9):1319-32.
PMID: 21626031
PMC: 11028898.
DOI: 10.1007/s00262-011-1032-4.
Insights into MHC class I antigen processing gained from large-scale analysis of class I ligands.
Mester G, Hoffmann V, Stevanovic S
Cell Mol Life Sci. 2011; 68(9):1521-32.
PMID: 21387142
PMC: 11114492.
DOI: 10.1007/s00018-011-0659-9.
Immune evasion proteins of murine cytomegalovirus preferentially affect cell surface display of recently generated peptide presentation complexes.
Lemmermann N, Gergely K, Bohm V, Deegen P, Daubner T, Reddehase M
J Virol. 2009; 84(3):1221-36.
PMID: 19906905
PMC: 2812335.
DOI: 10.1128/JVI.02087-09.
HNPCC versus sporadic microsatellite-unstable colon cancers follow different routes toward loss of HLA class I expression.
Dierssen J, de Miranda N, Ferrone S, van Puijenbroek M, Cornelisse C, Fleuren G
BMC Cancer. 2007; 7:33.
PMID: 17316446
PMC: 1808468.
DOI: 10.1186/1471-2407-7-33.
High epitope expression levels increase competition between T cells.
Scherer A, Salathe M, Bonhoeffer S
PLoS Comput Biol. 2006; 2(8):e109.
PMID: 16933984
PMC: 1550274.
DOI: 10.1371/journal.pcbi.0020109.
Protective cytotoxic T-cell responses induced by venezuelan equine encephalitis virus replicons expressing Ebola virus proteins.
Olinger G, Bailey M, Dye J, Bakken R, Kuehne A, Kondig J
J Virol. 2005; 79(22):14189-96.
PMID: 16254354
PMC: 1280180.
DOI: 10.1128/JVI.79.22.14189-14196.2005.
Generation of human tumor-specific CTLs in HLA-A2.1-transgenic mice using unfractionated peptides from eluates of human primary breast and ovarian tumors.
Gritzapis A, Sotiriadou N, Papamichail M, Baxevanis C
Cancer Immunol Immunother. 2004; 53(11):1027-40.
PMID: 15164233
PMC: 11033028.
DOI: 10.1007/s00262-004-0541-9.
The Tübingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy.
Singh-Jasuja H, Emmerich N, Rammensee H
Cancer Immunol Immunother. 2004; 53(3):187-95.
PMID: 14758508
PMC: 11032959.
DOI: 10.1007/s00262-003-0480-x.
Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein.
Wilson J, HART M
J Virol. 2001; 75(6):2660-4.
PMID: 11222689
PMC: 115890.
DOI: 10.1128/JVI.75.6.2660-2664.2001.